These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 12494220)

  • 1. [Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin].
    Bubnova MG; Aronov DM; Perova NV; Olfer'ev AM; Golubev MA; Mel'kina OE; Zhasminova VG
    Kardiologiia; 2002; 42(1):27-32. PubMed ID: 12494220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin.
    Imagawa DK; Dawson S; Holt CD; Kirk PS; Kaldas FM; Shackleton CR; Seu P; Rudich SM; Kinkhabwala MM; Martin P; Goldstein LI; Murray NG; Terasaki PI; Busuttil RW
    Transplantation; 1996 Oct; 62(7):934-42. PubMed ID: 8878387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R
    Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.
    Liu TN; Wu CT; He F; Yuan W; Li SX; Li HW; Yu HY; Wu M
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hyperlipidemia and arteriosclerosis].
    Mabuchi H
    Nihon Naika Gakkai Zasshi; 1998 May; 87(5):950-7. PubMed ID: 9648450
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
    Tokoo M; Oguchi H; Terashima M; Tokunaga S; Miyasaka M; Hora K; Higuchi M; Yoshie T; Furuta S
    Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):397-403. PubMed ID: 1635284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Am J Cardiol; 2010 Sep; 106(6):787-92. PubMed ID: 20816118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Rizos E; Bairaktari E; Kostoula A; Hasiotis G; Achimastos A; Ganotakis E; Elisaf M; Mikhailidis DP
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load.
    Hiramitsu S; Miyagishima K; Ishii J; Matsui S; Naruse H; Shiino K; Kitagawa F; Ozaki Y
    J Cardiol; 2012 Nov; 60(5):395-400. PubMed ID: 22890076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.
    Tawata M; Miwa I; Tsuchiya K; Ozawa M; Shindo H; Wakasugi M; Onaya T
    Arzneimittelforschung; 1995 Jun; 45(6):704-8. PubMed ID: 7646575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pravastatin in patients with primary hyperlipidaemia.
    Mafauzy M; Mokhtar M; Wan Mohamad WB; Musalmah M
    Med J Malaysia; 1995 Sep; 50(3):272-7. PubMed ID: 8926908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine.
    Lee TM; Su SF; Chou TF; Tsai CH
    Am J Cardiol; 2001 Nov; 88(10):1108-13. PubMed ID: 11703953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial lipemia--effect of lipid-lowering drugs.
    Karpe F
    Atheroscler Suppl; 2002 May; 3(1):41-6. PubMed ID: 12044585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
    de Luis DA; Bachiller P; Aller R; Eiros Bouza J; Izaola O
    Nutrition; 2003 Oct; 19(10):903-4. PubMed ID: 14559329
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
    Nakamura N; Hamazaki T; Jokaji H; Minami S; Kobayashi M
    Int J Clin Lab Res; 1998; 28(3):192-5. PubMed ID: 9801932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk factors in elderly patients selected by primary care physicians for hypolipemic treatment].
    Barretto AC; Wajngarten M; Gebara OC; do Serro Azul JB; Pierri H; Nussbacher A; Pivotto L; Bellotti G; Pileggi F
    Arq Bras Cardiol; 1996 Aug; 67(2):93-8. PubMed ID: 9110440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.